Eisai increases the number of participants in Clarity AD study ...Middle East

News by : (PR Newswire) -
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for the...

Hence then, the article about eisai increases the number of participants in clarity ad study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Eisai increases the number of participants in Clarity AD study )

Last updated :

Also on site :

Most Viewed News
جديد الاخبار